<qa>  What is the second goal of the second goal?The secondary goal is to answer efficacy questions for which there is currently insufficient trial data available - for example SofosbuvirDaclatasvir appears to be an inexpensive pan genotypic solution to treat HCV globally but this is supported by a total n of less than 1000, and in some common genotypes, such as HCV Genotype 2, by an n of only 52 making for a wide margin of error and a high degree of uncertainty. 